Sobi™ keeps the Partner Products business area as an integral part of the company
Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that the Partner Products business area will remain an integral part of Sobi’s business model for the purpose of creating value when taking the company to the next level. Thereby, discussions regarding a potential sale of the Partner Products business area, which Sobi confirmed were ongoing in a press release on 3 February 2017, have been terminated. Sobi will continue to build on the results of the growing haemophilia business and create value through its other rare disease portfolios in the years to come.